Amgen spinout Kezar hits PhII hurdle, all eyes on June readout for drug’s other study

A 2015 spinout from Amgen’s $10.4 billion Onyx Pharmaceuticals purchase has hit a mid-stage roadblock.

Kezar Life Sciences’ lead asset, zetomipzomib, showed no differentiation from placebo in a mid-stage study in patients with two rare muscle inflammation and skin diseases. The Phase II PRESIDIO trial flop was seen in patients...

Click to view original post